These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10084469)

  • 1. Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial.
    Chervinsky P; Goldberg P; Galant S; Wang Y; Arledge T; Welch MB; Stahl E
    Chest; 1999 Mar; 115(3):642-8. PubMed ID: 10084469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of salmeterol in the maintenance treatment of asthma.
    Nathan RA; Seltzer JM; Kemp JP; Chervinsky P; Alexander WJ; Liddle R; Mills R
    Ann Allergy Asthma Immunol; 1995 Sep; 75(3):243-8. PubMed ID: 7552926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
    D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
    JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma.
    Wolfe J; Kreitzer S; Chervinsky P; Lawrence M; Wang Y; Reilly D; Davis S; Stahl E
    Ann Allergy Asthma Immunol; 2000 Mar; 84(3):334-40. PubMed ID: 10752919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma.
    Weinstein SF; Pearlman DS; Bronsky EA; Byrne A; Arledge T; Liddle R; Stahl E
    Ann Allergy Asthma Immunol; 1998 Jul; 81(1):51-8. PubMed ID: 9690573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
    Nelson HS; Weiss ST; Bleecker ER; Yancey SW; Dorinsky PM;
    Chest; 2006 Jan; 129(1):15-26. PubMed ID: 16424409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular safety of salmeterol in COPD.
    Ferguson GT; Funck-Brentano C; Fischer T; Darken P; Reisner C
    Chest; 2003 Jun; 123(6):1817-24. PubMed ID: 12796155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness.
    Rosenthal RR; Busse WW; Kemp JP; Baker JW; Kalberg C; Emmett A; Rickard KA
    Chest; 1999 Sep; 116(3):595-602. PubMed ID: 10492259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma.
    Wiegand L; Mende CN; Zaidel G; Zwillich CW; Petrocella VJ; Yancey SW; Rickard KA
    Chest; 1999 Jun; 115(6):1525-32. PubMed ID: 10378544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes.
    Lockey RF; DuBuske LM; Friedman B; Petrocella V; Cox F; Rickard K
    Chest; 1999 Mar; 115(3):666-73. PubMed ID: 10084473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial.
    Lemanske RF; Sorkness CA; Mauger EA; Lazarus SC; Boushey HA; Fahy JV; Drazen JM; Chinchilli VM; Craig T; Fish JE; Ford JG; Israel E; Kraft M; Martin RJ; Nachman SA; Peters SP; Spahn JD; Szefler SJ;
    JAMA; 2001 May 23-30; 285(20):2594-603. PubMed ID: 11368733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma.
    Malone R; LaForce C; Nimmagadda S; Schoaf L; House K; Ellsworth A; Dorinsky P
    Ann Allergy Asthma Immunol; 2005 Jul; 95(1):66-71. PubMed ID: 16095144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group.
    Simons FE
    N Engl J Med; 1997 Dec; 337(23):1659-65. PubMed ID: 9385125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol.
    Blake K; Pearlman DS; Scott C; Wang Y; Stahl E; Arledge T
    Ann Allergy Asthma Immunol; 1999 Feb; 82(2):205-11. PubMed ID: 10071526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma.
    Busse WW; Casale TB; Murray JJ; Petrocella V; Cox F; Rickard K
    Am J Manag Care; 1998 Nov; 4(11):1579-87. PubMed ID: 10338904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma.
    Wenzel SE; Lumry W; Manning M; Kalberg C; Cox F; Emmett A; Rickard K
    Ann Allergy Asthma Immunol; 1998 Jun; 80(6):463-70. PubMed ID: 9647268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
    Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
    Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma.
    Peters JI; Shelledy DC; Jones AP; Lawson RW; Davis CP; LeGrand TS
    Chest; 2000 Aug; 118(2):313-20. PubMed ID: 10936118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.